Mersana Therapeutics to Present at the Jefferies Global Healthcare Conference
31 mai 2018 16h01 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
19 mars 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Appoints David A. Spellman as Chief Financial Officer
12 mars 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at Upcoming Investor Conferences
07 févr. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals
08 janv. 2018 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
20 déc. 2017 16h01 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Added to NASDAQ Biotechnology Index
15 déc. 2017 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors
12 déc. 2017 08h00 HE
|
Mersana Therapeutics, Inc.
Trial to Study Patients in Ovarian, NSCLC and Other Cancers XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) --...
Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates
09 nov. 2017 16h01 HE
|
Mersana Therapeutics, Inc.
Received FDA Clearance of IND Application for XMT-1536, a First-in-Class Dolaflexin® Antibody Drug Conjugate Targeting NaPi2b XMT-1522 Phase 1 Trial Continues Enrollment of Patients with Advanced...
Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b
30 oct. 2017 07h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...